Author

Jeffrey Enejosa 1

1 AbbVie Inc.,North C

99.7% SUSTAINED VIROLOGIC RESPONSE RATE IN 369 HCV GENOTYPE 1B-INFECTED PATIENTS TREATED WITH LABEL-RECOMMENDED REGIMEN OF OMBITASVIR/PARITAPREVIR/R AND DASABUVIR WITH OR WITHOUT RIBAVIRIN

Jean-François Dufour, Heiner Wedemeyer, David E. Bernstein, Massimo Colombo, Manuel Romero-Gomez, Nancy Reau, Roger Trinh, Wangang Xie, Jeffrey Enejosa, Daniel E. Cohen, Marisol Martinez, Ira M. Jacobson

ADHERENCE TO PRESCRIBED DOSES OF ABT-450/R/OMBITASVIR, DASABUVIR, AND RIBAVIRIN IN THE PHASE 3 PEARL-II, PEARL-III, AND PEARL-IV TRIALS

David E. Bernstein, Rui Tato Marinho, Daniel E. Cohen, Fritz Bredeek, Ferenc Schneider, Gunnar Norkrans, Manuela Curescu, Michael Bennett, Marina Maevskaya, Jeffrey Fessel, Yan Luo, Jeffrey Enejosa

LOW INCIDENCE OF HYPERBILIRUBINAEMIA EVENTS WITH ABT-450/R/OMBITASVIR AND DASABUVIR WITH OR WITHOUT RIBAVIRIN IN HCV GENOTYPE-1 INFECTED PATIENTS

Manuel Romero-Gomez, Rui Tato Marinho, Ramon Vila, David E. Bernstein, Federico Rodriguez-Perez, Tarek Hassanein, K. Reddy, Naoky Tsai, Sandra Lovell, Jeffrey Enejosa, Yan Luo, Daniel E. Cohen, Marcos Pedrosa, Massimo Colombo

MANAGEMENT OF HAEMOGLOBIN DECREASE IN PATIENTS TREATED WITH ABT-450/RITONAVIR/OMBITASVIR AND DASABUVIR WITH OR WITHOUT RIBAVIRIN IN HCV GENOTYPE 1-INFECTED PATIENTS

Daniel Forton, Hendrik Reesink, David E. Bernstein, Thomas Sepe, John Vierling, William King, Yiran Hu, Jeffrey Enejosa, Daniel E. Cohen, Yan Luo, Marcos Pedrosa, Peter Ferenci

PATIENT-REPORTED OUTCOMES WITH UPADACITINIB IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: PHASE 2 RESULTS FROM CELEST STUDY

Laurent Peyrin-Biroulet, Edouard Louis, Edward V Loftus Jr, Namita Tundia, Mahesh Fuldeore, Ana P. Lacerda, Jeffrey Enejosa, Aileen L Pangan

SAFETY OF ABT-450/R/OMBITASVIR + DASABUVIR WITH OR WITHOUT RIBAVIRIN IN HCV GENOTYPE 1-INFECTED PATIENTS: RESULTS FROM PEARL II, PEARL III, AND PEARL IV

Richard Aspinall, Jacob Lalezari, Yan Luo, Ronald Pruitt, Velimir Luketic, Giovanni Gaeta, Iwona Olszok, William King, Selim Gürel, Yiran Hu, Jeffrey Enejosa, Daniel E. Cohen, Nancy Shulman

SVR12 OF 99% ACHIEVED WITH A RIBAVIRIN-FREE REGIMEN OF ABT-450/R/OMBITASVIR AND DASABUVIR IN HCV GENOTYPE 1B-INFECTED PATIENTS

Andreas Maieron, Massimo Puoti, Jeffrey Enejosa, Ziv Ari, Gunnar Norkrans, Manuel Romero-Gomez, Daniel E. Cohen, Thomas Podsadecki

Item 1 - 7 / 7
1